新冠肺炎患者慢性疼痛的横断面研究

IF 1 4区医学 Q3 EMERGENCY MEDICINE

Signa Vitae Pub Date : 2021-09-15 DOI:10.22514/sv.2021.172

A. Liampas, C. Ioannou, A. Artemiadis, G. Hadjigeorgiou, P. Zis

{"title":"新冠肺炎患者慢性疼痛的横断面研究","authors":"A. Liampas, C. Ioannou, A. Artemiadis, G. Hadjigeorgiou, P. Zis","doi":"10.22514/sv.2021.172","DOIUrl":null,"url":null,"abstract":"Background: Coronavirus disease 2019 (COVID-19) is a contagious disease caused by SARS-CoV-2. Symptoms of COVID-19 are variable, but often include fever, cough, headache, fatigue, breathing difficulties, and loss of smell or taste. Neurological complications include cerebrovascular incidents, acute polyneuropathy and myelitis. The aim of this cross-sectional study was to establish the prevalence of chronic pain in COVID-19 patients. Methods: All participants were prospectively evaluated. Pain was assessed with the use of the painDETECT and the DN4 questionnaires. Results: Fifty-two COVID019 patients (67% females, mean age 48.4 ± 16.1 years) and 52 age and gender matched healthy volunteers were recruited. Patients were evaluated on average 4.2 ± 2.9 months after being diagnosed with COVID-19. From the classic acute COVID-19 symptoms, 50% had anosmia/hyposmia, 48% ageusia/hypogeusia, 48% fatigue, 40% cough, 39% headache, 35% myalgias and 31% fever. The prevalence of chronic pain was 70% in the COVID-19 group and 73% in the healthy volunteer group. The most commonly reported painful area in both groups was lower back (35% in the COVID-19 group and 31% in the healthy control group). In 7 patients chronic pain (6 neuropathic, 1 nociceptive) developed after COVID-19 whereas 3 patients reported worsening of their pre-existing chronic pain (2 neuropathic, 1 nociceptive). In the COVID-19 group, patients with pain were significantly older compared to patients without (51.8 ± 17.0 years vs 40.9 ± 10.7 years, p = 0.022). No differences between the two sub-groups were found regarding gender, BMI, COVID-19 symptoms, COVID-19 symptoms duration or interval since COVID-19 infection. Conclusions: Chronic pain is very prevalent in patients suffered from COVID-19 and its prevalence is similar to the prevalence observed in the general population. However, one in 5 COVID-19 patients reports that chronic pain developed or deteriorated after their infection. Chronic pain, particularly neuropathic, should be considered as a symptom of the post-COVID syndrome. © 2021, Pharmamed Mado Ltd. All rights reserved.","PeriodicalId":49522,"journal":{"name":"Signa Vitae","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chronic pain in patients with COVID-19: Cross sectional study\",\"authors\":\"A. Liampas, C. Ioannou, A. Artemiadis, G. Hadjigeorgiou, P. Zis\",\"doi\":\"10.22514/sv.2021.172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Coronavirus disease 2019 (COVID-19) is a contagious disease caused by SARS-CoV-2. Symptoms of COVID-19 are variable, but often include fever, cough, headache, fatigue, breathing difficulties, and loss of smell or taste. Neurological complications include cerebrovascular incidents, acute polyneuropathy and myelitis. The aim of this cross-sectional study was to establish the prevalence of chronic pain in COVID-19 patients. Methods: All participants were prospectively evaluated. Pain was assessed with the use of the painDETECT and the DN4 questionnaires. Results: Fifty-two COVID019 patients (67% females, mean age 48.4 ± 16.1 years) and 52 age and gender matched healthy volunteers were recruited. Patients were evaluated on average 4.2 ± 2.9 months after being diagnosed with COVID-19. From the classic acute COVID-19 symptoms, 50% had anosmia/hyposmia, 48% ageusia/hypogeusia, 48% fatigue, 40% cough, 39% headache, 35% myalgias and 31% fever. The prevalence of chronic pain was 70% in the COVID-19 group and 73% in the healthy volunteer group. The most commonly reported painful area in both groups was lower back (35% in the COVID-19 group and 31% in the healthy control group). In 7 patients chronic pain (6 neuropathic, 1 nociceptive) developed after COVID-19 whereas 3 patients reported worsening of their pre-existing chronic pain (2 neuropathic, 1 nociceptive). In the COVID-19 group, patients with pain were significantly older compared to patients without (51.8 ± 17.0 years vs 40.9 ± 10.7 years, p = 0.022). No differences between the two sub-groups were found regarding gender, BMI, COVID-19 symptoms, COVID-19 symptoms duration or interval since COVID-19 infection. Conclusions: Chronic pain is very prevalent in patients suffered from COVID-19 and its prevalence is similar to the prevalence observed in the general population. However, one in 5 COVID-19 patients reports that chronic pain developed or deteriorated after their infection. Chronic pain, particularly neuropathic, should be considered as a symptom of the post-COVID syndrome. © 2021, Pharmamed Mado Ltd. All rights reserved.\",\"PeriodicalId\":49522,\"journal\":{\"name\":\"Signa Vitae\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2021-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Signa Vitae\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.22514/sv.2021.172\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"EMERGENCY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Signa Vitae","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.22514/sv.2021.172","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"EMERGENCY MEDICINE","Score":null,"Total":0}

引用次数: 0

摘要

背景：2019冠状病毒病（新冠肺炎）是一种由SARS-CoV-2引起的传染性疾病。新冠肺炎的症状多种多样，但通常包括发烧、咳嗽、头痛、疲劳、呼吸困难以及嗅觉或味觉丧失。神经系统并发症包括脑血管事件、急性多发性神经病和脊髓炎。这项横断面研究的目的是确定新冠肺炎患者慢性疼痛的患病率。方法：对所有参与者进行前瞻性评价。使用painDETECT和DN4问卷对疼痛进行评估。结果：招募了52名新冠肺炎患者（67%为女性，平均年龄48.4±16.1岁）和52名年龄和性别匹配的健康志愿者。患者在被诊断为新冠肺炎后平均4.2±2.9个月接受评估。在典型的急性新冠肺炎症状中，50%的患者出现嗅觉缺失/嗅觉减退，48%的患者出现老年性嗅觉减退/嗅觉减退、48%的患者疲劳、40%的患者咳嗽、39%的患者头痛、35%的患者肌痛和31%的患者发热。慢性疼痛的患病率在新冠肺炎组为70%，在健康志愿者组为73%。两组中最常见的疼痛区域是下背部（新冠肺炎组为35%，健康对照组为31%）。在7名患者中，新冠肺炎后出现慢性疼痛（6例神经性疼痛，1例伤害性疼痛），而3名患者报告其先前存在的慢性疼痛恶化（2例神经性症状，1例疼痛性疼痛）。在新冠肺炎组中，疼痛患者的年龄明显高于无疼痛患者（51.8±17.0岁vs 40.9±10.7岁，p=0.022）。两个子组在性别、BMI、新冠肺炎症状、新冠肺炎症状自新冠肺炎感染以来的持续时间或间隔方面未发现差异。结论：慢性疼痛在新冠肺炎患者中非常普遍，其患病率与普通人群中观察到的患病率相似。然而，五分之一的新冠肺炎患者报告称，他们感染后出现或恶化了慢性疼痛。慢性疼痛，尤其是神经性疼痛，应被视为新冠肺炎后综合征的症状。©2021，Pharmamed Mado有限公司保留所有权利。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Chronic pain in patients with COVID-19: Cross sectional study

Background: Coronavirus disease 2019 (COVID-19) is a contagious disease caused by SARS-CoV-2. Symptoms of COVID-19 are variable, but often include fever, cough, headache, fatigue, breathing difficulties, and loss of smell or taste. Neurological complications include cerebrovascular incidents, acute polyneuropathy and myelitis. The aim of this cross-sectional study was to establish the prevalence of chronic pain in COVID-19 patients. Methods: All participants were prospectively evaluated. Pain was assessed with the use of the painDETECT and the DN4 questionnaires. Results: Fifty-two COVID019 patients (67% females, mean age 48.4 ± 16.1 years) and 52 age and gender matched healthy volunteers were recruited. Patients were evaluated on average 4.2 ± 2.9 months after being diagnosed with COVID-19. From the classic acute COVID-19 symptoms, 50% had anosmia/hyposmia, 48% ageusia/hypogeusia, 48% fatigue, 40% cough, 39% headache, 35% myalgias and 31% fever. The prevalence of chronic pain was 70% in the COVID-19 group and 73% in the healthy volunteer group. The most commonly reported painful area in both groups was lower back (35% in the COVID-19 group and 31% in the healthy control group). In 7 patients chronic pain (6 neuropathic, 1 nociceptive) developed after COVID-19 whereas 3 patients reported worsening of their pre-existing chronic pain (2 neuropathic, 1 nociceptive). In the COVID-19 group, patients with pain were significantly older compared to patients without (51.8 ± 17.0 years vs 40.9 ± 10.7 years, p = 0.022). No differences between the two sub-groups were found regarding gender, BMI, COVID-19 symptoms, COVID-19 symptoms duration or interval since COVID-19 infection. Conclusions: Chronic pain is very prevalent in patients suffered from COVID-19 and its prevalence is similar to the prevalence observed in the general population. However, one in 5 COVID-19 patients reports that chronic pain developed or deteriorated after their infection. Chronic pain, particularly neuropathic, should be considered as a symptom of the post-COVID syndrome. © 2021, Pharmamed Mado Ltd. All rights reserved.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Signa Vitae 医学-急救医学

CiteScore

1.30

自引率

9.10%

发文量

审稿时长

3 months

期刊介绍： Signa Vitae is a completely open-access，peer-reviewed journal dedicate to deliver the leading edge research in anaesthesia, intensive care and emergency medicine to publics. The journal’s intention is to be practice-oriented, so we focus on the clinical practice and fundamental understanding of adult, pediatric and neonatal intensive care, as well as anesthesia and emergency medicine. Although Signa Vitae is primarily a clinical journal, we welcome submissions of basic science papers if the authors can demonstrate their clinical relevance. The Signa Vitae journal encourages scientists and academicians all around the world to share their original writings in the form of original research, review, mini-review, systematic review, short communication, case report, letter to the editor, commentary, rapid report, news and views, as well as meeting report. Full texts of all published articles, can be downloaded for free from our web site.